A
Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
XETRA:APPH
Price:
11.4
EUR
0.88%
Market Closed
Market Cap:
96.9m
EUR
Apontis Pharma AG
Long-Term Debt
|
Apontis Pharma AG
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Long-Term Debt
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Long-Term Debt
$17.9m
|
CAGR 3-Years
108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Long-Term Debt
€35.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Merck KGaA
XETRA:MRK
|
Long-Term Debt
€7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Long-Term Debt
€904.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Long-Term Debt
€65.8m
|
CAGR 3-Years
669%
|
CAGR 5-Years
205%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
APPH
Intrinsic Value
16.11
EUR
Undervaluation 29%
A
See Also
What is Apontis Pharma AG's Long-Term Debt?
Long-Term Debt
0
EUR
0
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Long-Term Debt amounts to 0 EUR.
You don't have any saved screeners yet